Brink Therapeutics
French tech company | Builders Republic
About
Gene-editing biotech engineering recombinases — enzymes that insert or swap DNA at targeted sites without cutting both strands — using directed evolution and computational design to make them programmable, with first applications in CAR-T cell therapies for blood cancers and ambitions toward solid tumors and rare genetic diseases.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Seed
- Founded
- 2024
- City
- PARIS
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 3.5 M€ raised since 2020
Funding rounds
- Seed — 2025